<DOC>
	<DOCNO>NCT00958854</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine cyclophosphamide , work different way stop growth cancer cell , either kill cell stop dividing . Thalidomide may stop growth lymphoma block blood flow cancer . Giving fludarabine cyclophosphamide together thalidomide may kill cancer cell . PURPOSE : This phase II trial study well give fludarabine cyclophosphamide together thalidomide work treat patient angioimmunoblastic T-cell lymphoma .</brief_summary>
	<brief_title>Fludarabine , Cyclophosphamide , Thalidomide Treating Patients With Angioimmunoblastic T-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient angioimmunoblastic T-cell lymphoma chemotherapy comprise fludarabine cyclophosphamide . Secondary - Assess incremental anatomical molecular response rate patient treatment thalidomide . - Determine toxicity treatment fludarabine cyclophosphamide follow thalidomide . - Assess progression-free overall survival patient . - Develop detailed pathological description disease presentation relapse . - Assess number circulate clonal T cell presentation thalidomide treatment . - Screen possible etiological virus presentation . - Evaluate evolution EBV viral load follow-up . OUTLINE : This multicenter study . Patients receive oral IV fludarabine oral IV cyclophosphamide daily day 1-3 . Courses repeat every 28 day 4-6 course absence disease progression unacceptable toxicity . Beginning least 4 week completion chemotherapy , patient achieve least stable disease receive oral thalidomide daily least 6 month . Lymph node , marrow , peripheral blood collect periodically research study . After completion study therapy , patient follow every 3 month 2 year every 6 month thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose angioimmunoblastic Tcell lymphoma Measurable disease ( i.e. , anatomically assessable ) PATIENT CHARACTERISTICS : WHO/ECOG performance status 02 Serum creatinine ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception , , study treatment No known seropositivity hepatitis B virus , hepatitis C virus , HIV No active second malignancy concomitant serious medical condition , particular peripheral neuropathy PRIOR CONCURRENT THERAPY : No prior chemotherapy angioimmunoblastic Tcell lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
</DOC>